Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | Director | June 20, 2018 | June 22, 2018 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| MyoKardia, Inc.MYOK · Entity 145206 | Director | November 29, 2016 | December 01, 2016 |
| PLIANT THERAPEUTICS, INC.PLRX · Entity 7022 | Director | June 29, 2021 | July 01, 2021 |
| Population Health Investment Co., Inc.PHIC · Entity 136038 | Director | January 26, 2021 | January 27, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 919,876 |
Reported balance
After 2026-06-22 transaction · row 1
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 919,876 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
Global Blood Therapeutics, Inc.
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.25 · Expires 2028-06-19 | Direct | 15,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest and become exercisable in 12 equal monthly installments, with the first installment on July 20 2018, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
MyoKardia, Inc.
Report date November 29, 2016 · Filed December 01, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2016-11-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-11-29 · Other · Disposed 0 · Balance 0 F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. |
| Common StockSEC Table I · non-derivative | Direct | 6,496 |
Reported balance
Holding disclosure · report date 2016-11-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,496 F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures II, L.P. ("TRV II"), Third Rock Ventures GP II, L.P. ("TRV GP II") and TRV GP II, LLC ("TRV GP II LLC"), TRV II distributed on November 29, 2016, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to TRV GP II, the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The reporting person is a partner of TRV GP II, which is the general partner of TRV II. The reporting person disclaims beneficial ownership over the shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F3: The shares are directly held by the reporting person. Includes Shares received in the distributions described in footnote (1) above.
PLIANT THERAPEUTICS, INC.
Report date June 29, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.20 · Expires 2031-06-28 | Direct | 13,286 |
Reported balance
After 2021-06-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-29 · Grant · Acquired 13,286 · Balance 13,286 F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.
Population Health Investment Co., Inc.
Report date January 26, 2021 · Filed January 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 43,125 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Other · Acquired 43,125 · Balance 43,125 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-249756) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for share splits, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
F2: In connection with Mr. Homcy's election as an independent director of the issuer, 43,125 Class B ordinary shares of the issuer were transferred by Population Health Investment Holding, Inc. to Mr. Homcy for $250.00, or approximately $0.0058 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PORTOLA PHARMACEUTICALS INC
Report date March 28, 2019 · Filed April 01, 2019
Section 16 reporting ended · disclosed 2019-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.59 · Expires 2029-03-27 | Direct | 10,000 |
Reported balance
After 2019-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-28 · Grant · Acquired 10,000 · Balance 10,000 F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options shall vest on the one (1) year anniversary of the date of the grant subject to the terms of the applicable option agreement and option plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000633 · wk-form4_1782338768.xml · derivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000633 · wk-form4_1782338768.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,876 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 20, 2026 Filed Jun 23, 2026 22:46 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 788 | $66.27 | $52,220.76 |
DisclosureSEC source: 0001470831-26-000569 · wk-form4_1782254762.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,886 F1 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 2,196 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:25 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001192591-26-000004 · form4-06102026_080626.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-06-07 F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:13 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GiftCommon Stock | 7,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001192591-26-000002 · form4-05062026_080559.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,113 F1 · kind: The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5. F2 · balance_after: The total reflected in Column 5 of Table I includes shares which were previously held directly by the Charles J. Homcy Revocable Trust UA 11/4/1998. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:24 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | OtherCommon Stock | 1,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001192591-25-000010 · form4-11212025_091144.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,113 F1 · kind: The reported transaction represents the receipt by the reporting person of his pro rata share of a distribution made by one or more entities affiliated with Third Rock Ventures, for no consideration, of shares of the Issuer's common stock, which distribution was made in accordance with the exemption afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 20:46 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GiftCommon Stock | 28,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001192591-25-000008 · form4-10272025_081019.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,624 F1 · kind: The reported transaction represents a gift, for no consideration, which is exempt pursuant to Rule 16b-5. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:15 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.67 | $0.00 |
DisclosureSEC source: 0001192591-25-000005 · form4-09242025_080916.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| August 11, 2025 Filed Aug 12, 2025 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 50,000 | $48.00 | $2,400,000.00 |
DisclosureSEC source: 0000950170-25-107510 · ownership.xml · nonDerivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 916,674 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 58,338 | $46.64 | $2,720,849.32 |
DisclosureSEC source: 0000950170-25-107510 · ownership.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 966,674 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025. F3 · price: Represents the weighted average sale price of the shares sold from $46.40 to $46.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 23:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 191,662 | $45.87 | $8,791,593.44 |
DisclosureSEC source: 0000950170-25-107510 · ownership.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,025,012 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 8, 2025. F2 · price: Represents the weighted average sale price of the shares sold from $45.395 to $46.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 21:54 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GiftCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-091764 · ownership.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,216,674 Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:56 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089648 · ownership.xml · derivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:56 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089648 · ownership.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,236,674 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries D-1 Preferred Stock · Derivative | 71,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 6 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 7,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F3 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F3 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F4 · ownership.nature: These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the "Trust"), of which the reporting person is the trustee. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries C Preferred Stock · Derivative | 169,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 5 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date. F2 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date. F2 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date. F2 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries B Preferred Stock · Derivative | 72,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 4 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,807 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date. F1 · derivative.exercise_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date. F1 · derivative.expiration_date: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionCommon Stock | 7,422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · nonDerivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series D-1 Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1037236801. The securities have no expiration date. F4 · ownership.nature: These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the "Trust"), of which the reporting person is the trustee. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionCommon Stock | 20,717 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series C Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1222996332. The securities have no expiration date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionCommon Stock | 8,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Pursuant to the Issuer's Restated Certificate of Incorporation, upon closing of the Issuer's initial public offering of its Common Stock, each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock at a ratio of 1-for-0.1211056427. The securities have no expiration date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 45,638 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 15 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,638 Underlying: Common Stock · 45,638 shares Expires 2034-12-08 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F13 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,675 | Not disclosed Strike: $14.08 | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 14 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,675 shares Expires 2034-04-22 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F10 · price: This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. F12 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 46,675 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 13 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,675 Underlying: Common Stock · 46,675 shares Expires 2034-04-22 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F12 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,704 | Not disclosed Strike: $17.74 | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 12 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,704 shares Expires 2033-03-08 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F10 · price: This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. F11 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 5,704 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 11 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,704 Underlying: Common Stock · 5,704 shares Expires 2033-03-08 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F11 · derivative.exercise_date: The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,385 | Not disclosed Strike: $11.19 | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 10 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,385 shares Expires 2031-03-03 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F10 · price: This option, which was first granted to the reporting person prior to the Issuer registering a class of equity securities under Section 12 of the Exchange Act, was canceled and exchanged for a new option having a lower exercise price in connection with an option repricing approved by the Issuer's Board of Directors on December 9, 2024. All terms of the option remained unchanged other than the exercise price. F9 · derivative.exercise_date: Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2024. Read SEC document |
| December 09, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 80,385 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 9 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,385 Underlying: Common Stock · 80,385 shares Expires 2031-03-03 F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F9 · derivative.exercise_date: Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 1, 2024. Read SEC document |
| November 26, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | Conversion8% Convertible Note due 2026 · Derivative | Not disclosed | $78,961.64 Strike: $1.10 | $75,000.00 |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 8 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: Not disclosed Underlying: Series D-1 Preferred Stock · 71,564 shares Expires 2026-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Pursuant to the terms of the Convertible Note (defined below), the conversion price for the principal balance of the Convertible Note and all accrued and unpaid interest thereon was the lesser of: (i) the share price paid for the issuance of the Issuer's Series C Preferred Stock and (ii) the offering price for the Issuer's next private placement or its initial public offering, in each case subject to a 20% discount. Accordingly, the Convertible Note was converted into shares of the Issuer's Series D-1 Preferred Stock at a price per share that amounted to 80% of the price at which shares of the Issuer's Series D Preferred Stock were issued. F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F8 · price: On November 26, 2024 (the "Conversion Date"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the "Convertible Note"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon. The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026. Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336. F8 · derivative.exercise_date: On November 26, 2024 (the "Conversion Date"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the "Convertible Note"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon. The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026. Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336. F8 · derivative.expiration_date: On November 26, 2024 (the "Conversion Date"), the Trust surrendered to the Issuer a convertible note originally issued on March 29, 2024 in the principal amount of $75,000.00 (the "Convertible Note"), in exchange for 71,564 shares of the Issuer's Series D-1 Preferred Stock, in satisfaction of the aggregate principal owed thereunder, together with accrued and unpaid interest thereon. The terms of the Convertible Note provided for its automatic conversion upon the earlier of the completion of the Issuer's next private placement financing or its initial public offering, and the Convertible Note was subject to a final maturity date of December 15, 2026. Accordingly, the Convertible Note was converted upon the closing of the Issuer's Series D Preferred Stock financing into shares of the Issuer's Series D-1 Preferred Stock at a conversion price of $1.10336. F4 · ownership.nature: These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the "Trust"), of which the reporting person is the trustee. Read SEC document |
| November 26, 2024 Filed Feb 4, 2025 21:35 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | ConversionSeries D-1 Preferred Stock · Derivative | 71,564 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002956 · form4-02042025_090216.xml · derivative · entry 7 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,422 Underlying: Common Stock · 7,422 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336. As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801. While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date. F6 · date: This transaction is an exempt transaction with the Issuer which occurred prior to the Issuer registering a class of equity securities under Section 12 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is reported herein as a transaction pursuant to Rule 16a-2(a). All numbers of shares and applicable security prices have been adjusted to reflect a 1:9.641 reverse stock split of the Issuer's Common Stock effected on January 24, 2025 and, where applicable, the conversion of the Issuer's series of Preferred Stock to Common Stock upon completion of its initial public offering. F5 · price: Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336. As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801. While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date. F5 · derivative.exercise_date: Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336. As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801. While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date. F5 · derivative.expiration_date: Shares of the Issuer's Series D-1 Preferred Stock were originally issued with a conversion price of $1.10336. As reported above, pursuant to the Issuer's Restated Certificate of Incorporation, and by virtue of the Issuer's previous 1:9.641 reverse stock split effected on January 24, 2025, upon completion of the Issuer's initial public offering of its Common Stock, shares of Series D-1 Preferred Stock were converted into shares of Common Stock at a post-reverse split adjusted ratio of 1-for-0.1037236801. While they were outstanding, shares of the Issuer's Series D-1 Preferred Stock were convertible at the election of the holder at any time and the securities had no expiration date. F4 · ownership.nature: These securities are directly held by the Charles J. Homcy Revocable Trust UA 11/4/1998 (the "Trust"), of which the reporting person is the trustee. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077445 · ownership.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017894 · ownership.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,509 | $37.21 | $56,149.89 |
DisclosureSEC source: 0000950170-24-017894 · ownership.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,230,085 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017894 · ownership.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,231,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 838 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056011 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,760 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,301 | $28.86 | $37,546.86 |
DisclosureSEC source: 0001209191-23-056011 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,226,996 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056011 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,228,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046514 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,520 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,301 | $29.80 | $38,769.80 |
DisclosureSEC source: 0001209191-23-046514 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,224,537 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046514 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,225,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 1,251 shares acquired on August 15, 2023 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:20 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039380 · doc4.xml · derivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,759 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030593 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,280 Underlying: Common Stock · 3,759 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,300 | $14.09 | $18,317.00 |
DisclosureSEC source: 0001209191-23-030593 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,220,827 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,759 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:05 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,759 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-030593 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,222,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011452 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,039 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,534 | $12.64 | $19,389.76 |
DisclosureSEC source: 0001209191-23-011452 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218,368 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:18 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011452 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 1,891 shares acquired on February 15, 2023 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057982 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,799 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,301 | $9.64 | $12,541.64 |
DisclosureSEC source: 0001209191-22-057982 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214,251 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,760 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,760 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-057982 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 840 shares acquired on February 17, 2021 and 1,497 shares acquired on August 15, 2022 by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:33 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,760 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046731 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,559 Underlying: Common Stock · 3,760 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.